AMDS Hybrid Prosthesis
Artivion, Inc · Decision date Jun 26, 2026
What did the FDA approve?
FDA records P250055 as an original PMA application. The recorded decision is approval, dated Jun 26, 2026.
FDA approval order statement
The AMDS Hybrid Prosthesis is indicated for use in patients with acute DeBakey Type I aortic dissections with malperfusion (including cerebral, visceral, renal, and peripheral malperfusion) and a primary entry tear within the ascending aorta proximal to the innominate artery, who are undergoing open surgical repair within 0-14 days of diagnosis.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 26, 2026
Regulatory record facts
- Identifier
- P250055
- Regulatory pathway
- Premarket approval application
- Applicant
- Artivion, Inc
- Product code
- QSK
- Decision code
- APPR
- Decision date
- Jun 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.
- Applicant
- Artivion, Inc
- Product code
- QSK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250055 received
Application receipt date recorded by FDA.
P250055 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250055. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code QSK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Thoraflex HybridP210006/S018 | Vascutek, Ltd. | PMA supplement | Sep 8, 2026 | FDA |
Thoraflex HybridP210006/S019 | Vascutek, Ltd. | PMA supplement | Jun 24, 2026 | FDA |
Thoraflex HybridP210006/S017 | Vascutek, Ltd. | PMA supplement | Apr 20, 2026 | FDA |
Thoraflex HybridP210006/S016 | Vascutek, Ltd. | PMA supplement | Jan 29, 2026 | FDA |
Thoraflex HybridP210006/S015 | Vascutek, Ltd. | PMA supplement | Oct 29, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Artivion, Inc
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1655 Roberts Blvd. NW, Kennesaw, GA, 30144
Sources and methodology
- Original FDA record: P250055
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



